BrightSpring Health Services Announces Onco360® Was Selected as National Pharmacy Partner for OJEMDA™
LOUISVILLE, Ky., May 20, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud that its company, Onco360®, one of the nation’s largest independent oncology pharmacies, is being selected as a pharmacy partner by Day One Biopharmaceuticals for OJEMDA™, a cutting-edge treatment for children diagnosed with certain central nervous system tumors.
- LOUISVILLE, Ky., May 20, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud that its company, Onco360®, one of the nation’s largest independent oncology pharmacies, is being selected as a pharmacy partner by Day One Biopharmaceuticals for OJEMDA™, a cutting-edge treatment for children diagnosed with certain central nervous system tumors.
- LGG is the most common central nervous system tumor in children, representing 30% of pediatric brain tumors.
- BRAF is the most commonly altered gene in pediatric LGG, as 75% of patients have BRAF alterations.
- We’re proud to partner with Day One Biopharmaceuticals to become a specialty provider for OJEMDA™,” said Benito Fernandez, Chief Commercial Officer at Onco360®.